Physician profile
Albert Scott
NPI 1306839808
$5,241.01
in general payments reported to CMS, 2019-2025
30 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $163 · 2021: $275 · 2022: $422 · 2023: $508 · 2024: $1,532 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,366.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,632.35 | 2024-2025 | |
| Abbvie INC. | $384.74 | 2020-2025 | Lo Loestrin Fe, Liletta |
| Daiichi Sankyo INC. | $275.56 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $269.06 | 2019-2025 | Aptima, Novasure |
| Astellas Pharma US INC | $247.60 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $225.50 | 2019-2025 | Slynd |
| Myriad Women'S Health, INC. | $149.78 | 2023 | Myrisk |
| Shield Therapeutics INC | $130.46 | 2023-2024 | Accrufer |
| Mayne Pharma Commercial LLC | $126.89 | 2022-2025 | |
| Gen-Probe, INC. | $106.65 | 2019 | |
| Sumitomo Pharma America, INC. | $89.44 | 2023-2025 | Myfembree |
| Pfizer INC. | $84.78 | 2019-2024 | |
| Aspira Women'S Health INC | $83.20 | 2022 | |
| Applied Medical Resources Corporation | $58.39 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $51.88 | 2023 | Vivjoa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $42.39 | 2023 | |
| Agile Therapeutics, INC. | $39.15 | 2022-2024 | Twirla |
| Therapeuticsmd, INC. | $38.23 | 2019 | |
| Lupin INC. | $31.82 | 2019 | |
| Baxter Healthcare | $19.55 | 2025 | Tisseel |
| Exact Sciences Corporation | $19.13 | 2024 | Cologuard Collection Kit |
| Coopersurgical, INC. | $18.46 | 2022 | |
| Scynexis, INC. | $16.33 | 2022 | |
| Myovant Sciences INC. | $16.05 | 2021 | |
| Amgen INC. | $16.02 | 2020 | |
| Evofem Biosciences, INC. | $15.21 | 2021 | |
| Minerva Surgical, INC | $15.05 | 2023 | |
| Mylan Pharmaceuticals INC. | $13.97 | 2022 | |
| Roche Diagnostics Corporation | $11.73 | 2019 | |
| Allergan, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.